Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Published on September 7, 2011 at 9:49 AM · No Comments

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD). Results showed MG01CI met the primary efficacy outcome, demonstrating a significant improvement on the Conners' Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms Score (CAARS-INV) compared to placebo (p<0.03).

“These results confirm previous clinical experience indicating MG01CI may have a quick onset of activity with few side effects, distinguishing it from other non-stimulant ADHD treatments”

In the study, 56 percent of subjects treated with MG01CI experienced an improvement in their CAARS-INV score of at least 25 percent, compared to 36 percent of patients in the placebo group (p<0.03). Additionally, 44 percent of the subjects treated with MG01CI demonstrated an improvement of more than 40 percent in their CAARS-INV score versus only 25 percent in the placebo group (p<0.04). MG01CI was well tolerated, with no drug-related serious adverse events reported and no clinically or statistically significant differences in adverse event profiles between the MG01CI and placebo treatment arms. Nausea and initial insomnia were more frequently reported in the MG01CI arm, yet the rate of patient discontinuation due to adverse events was similar in both groups (1.7%). Importantly, no increase in blood pressure or appetite suppression was recorded in the treatment group.

"ADHD is the most commonly studied and diagnosed chronic psychiatric disorder in children and adults, affecting about 3 to 5 percent of the population," said Iris Manor M.D., director of the ADHD Unit, Geha Mental Health Center in Petach Tikva, Israel. "I am very encouraged by the results of this trial, which warrants further clinical development of MG01CI, a novel non-stimulant drug that may benefit many people with ADHD."

In the trial, MGO1CI also demonstrated significant improvement on secondary endpoints, including the Adult ADHD Quality of Life Scale (AAQoL) and the Test of Variables of Attention (T.O.V.A.®) scores.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment